Inhibitor of DNA binding 2 (ID2) regulates key transcriptional programs in multiple myeloma

MLA

Mehmet Kemal Samur, et al. “Inhibitor of DNA Binding 2 (ID2) Regulates Key Transcriptional Programs in Multiple Myeloma.” Clinical Lymphoma Myeloma and Leukemia, vol. 19, Oct. 2019, pp. e98–99. EBSCOhost, https://doi.org/10.1016/j.clml.2019.09.160.

APA

Mehmet Kemal Samur, Yan Xu, Kenneth C. Anderson, Enrico Milan, Nicola Amodio, Eugenio Morelli, Nikhil C. Munshi, Simone Cenci, Mariateresa Fulciniti, Christopher J. Ott, Kenneth Wen, Matthew A. Lawlor, Fabio Ciceri, Raphael Szalat, & Tommaso Perini. (2019). Inhibitor of DNA binding 2 (ID2) regulates key transcriptional programs in multiple myeloma. Clinical Lymphoma Myeloma and Leukemia, 19, e98–e99. https://doi.org/10.1016/j.clml.2019.09.160

Chicago

Mehmet Kemal Samur, Yan Xu, Kenneth C. Anderson, Enrico Milan, Nicola Amodio, Eugenio Morelli, Nikhil C. Munshi, et al. 2019. “Inhibitor of DNA Binding 2 (ID2) Regulates Key Transcriptional Programs in Multiple Myeloma.” Clinical Lymphoma Myeloma and Leukemia 19 (October): e98–99. doi:10.1016/j.clml.2019.09.160.